<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Caladrius_Biosciences_Inc.</id>
	<title>Caladrius Biosciences Inc. - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=Caladrius_Biosciences_Inc."/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Caladrius_Biosciences_Inc.&amp;action=history"/>
	<updated>2026-05-16T23:03:15Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=Caladrius_Biosciences_Inc.&amp;diff=412707&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei Caladrius Biosciences Inc. listata cu simbolul US.CLBS  ==Descriere companie== Caladrius Biosciences, Inc.(www.caladrius.com) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FRE...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=Caladrius_Biosciences_Inc.&amp;diff=412707&amp;oldid=prev"/>
		<updated>2024-09-18T13:47:27Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei Caladrius Biosciences Inc. listata cu simbolul US.CLBS  ==Descriere companie== Caladrius Biosciences, Inc.(www.caladrius.com) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FRE...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei Caladrius Biosciences Inc. listata cu simbolul US.CLBS&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
Caladrius Biosciences, Inc.(www.caladrius.com) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.CLBS&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre Caladrius Biosciences Inc. (US.CLBS)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.CLBS&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.CLBS]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>